Journal
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY
Volume 14, Issue 1, Pages 58-61Publisher
SPRINGER WIEN
DOI: 10.1007/s12254-021-00674-9
Keywords
ASCO Annual Meeting 2020; Highlights; Pembrolizumab; Review; Tucatinib
Categories
Funding
- Medical University of Vienna
Ask authors/readers for more resources
The 2020 ASCO Annual Meeting highlighted several interesting studies in the field of breast cancer, including significant activity of pembrolizumab in metastatic triple-negative breast cancer, the role of olaparib in homologous recombination deficient tumors, different strategies of chemotherapy de-escalation in HER2-positive early stage disease, and the new standard-of-care using tucatinib in combination with trastuzumab and capecitabine for HER2-positive metastatic breast cancer with brain metastases.
The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in a virtual format due to the ongoing SARS-CoV-2 pandemic. Despite these unique circumstances, results of several interesting studies in the field of breast cancer (BC) were reported. While overall survival data are still missing, KEYNOTE-355 suggests significant activity of pembrolizumab when added to first-line chemotherapy in metastatic triple-negative breast cancer. TBCRC 048 evaluated the role of olaparib in homologous recombination deficient tumours due to genomic alterations other than germline BRCA1/2 mutations; clinically relevant activity was reported in patients with germline PALB2 and somatic BRCA1/2 mutations. In HER2-positive early stage disease, different strategies of chemotherapy de-escalation are under investigation, but the optimal approach is still not well defined. Updated results from the HER2CLIMB trial show that the third-generation HER2 tyrosine-kinase inhibitor tucatinib in combination with trastuzumab and capecitabine is the new standard-of-care for pretreated patients with HER2-positive metastatic BC with active brain metastases. Results from BYLieve supports the notion that the combination of endocrine therapy with the PIK3Ca inhibitor alpelisib is a reasonable treatment approach in hormone-receptor positive/HER2-negative BC after prior CDK4/6-inhibitor therapy. Finally, the ECOG-ACRIN 2108 trial failed to show a benefit for early surgery of the primary tumour in patients with metastatic BC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available